SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on August 1, 2002; DOI 10.1182/blood-2001-12-0264. This Article Full Text Full Text (PDF) All Versions of this Article: 2001-12-0264v1 100/13/4590    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Smith, M. T. Articles by Felix, C. A. Search for Related Content PubMed PubMed Citation Articles by Smith, M. T. Articles by Felix, C. A. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 December 2002, Vol. 100, No. 13, pp. 4590-4593 NEOPLASIA Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children Martyn T. Smith, Yunxia Wang, Christine F. Skibola, Diana J. Slater, Luca Lo Nigro, Peter C. Nowell, Beverly J. Lange, and Carolyn A. Felix From the Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley; the Division of Oncology, The Children's Hospital of Philadelphia, and the Department of Pathology and Laboratory Medicine and the Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA. An inactivating polymorphism at position 609 in the NAD(P)H:quinone oxidoreductase 1 gene (NQO1 C609T) is associated with an increased risk of adult leukemia. A small British study suggested that NQO1 C609T was associated with an increased risk of infant leukemias with MLL translocations, especially infant acute lymphoblastic leukemia (ALL) with t(4;11). We explored NQO1 C609T as a genetic risk factor in 39 pediatric de novo and 18 pediatric treatment-related leukemias with MLL translocations in the United States. Children with de novo B-lineage ALL without MLL translocations and a calculation of the expected genotype distribution in an ethnically matched population of disease-free subjects served as the comparison groups. Patients with de novo leukemias with MLL translocations were significantly more likely to be heterozygous at NQO1 C609T (odds ratio [OR] = 2.77, 95% confidence intervals [CI] 1.17-6.57; P = .02), and significantly more likely to have low/null NQO1 activity than patients with de novo B-lineage ALL without MLL translocations (OR = 2.47, 95% CI 1.08-5.68; P = .033). They were also significantly more likely to have low/null NQO1 activity than expected in an ethnically matched population of disease-free subjects (OR = 2.50, P = .02). Infants younger than 12 months old at diagnosis of leukemia with t(4;11) were most likely to have low/null NQO1 activity (OR > 10.0). Conversely, the distribution of NQO1 genotypes among patients with treatment-related leukemias with MLL translocations was not statistically different than in the comparison groups. The inactivating NQO1 polymorphism is associated with an increased risk of de novo leukemia with MLL translocations in infants and children. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: RE: "NQO1 POLYMORPHISMS AND DE NOVO CHILDHOOD LEUKEMIA: A HUGE REVIEW AND META-ANALYSIS" Am. J. Epidemiol., May 15, 2009; 169(10): 1280 - 1280. [Full Text] [PDF] N. Guha, J. S. Chang, A. P. Chokkalingam, J. L. Wiemels, M. T. Smith, and P. A. Buffler THE AUTHORS REPLY Am. J. Epidemiol., May 15, 2009; 169(10): 1279 - 1279. [Full Text] [PDF] M. Lanciotti and C. Dufour Re: "NQO1 POLYMORPHISMS AND DE NOVO CHILDHOOD LEUKEMIA: A HUGE REVIEW AND META-ANALYSIS" Am. J. Epidemiol., May 15, 2009; 169(10): 1278 - 1279. [Full Text] [PDF] N. Guha, J. S. Chang, A. P. Chokkalingam, J. L. Wiemels, M. T. Smith, and P. A. Buffler NQO1 Polymorphisms and De Novo Childhood Leukemia: A HuGE Review and Meta-Analysis Am. J. Epidemiol., December 1, 2008; 168(11): 1221 - 1232. [Abstract] [Full Text] [PDF] K. Iskander, R. J. Barrios, and A. K. Jaiswal Disruption of NAD(P)H:Quinone Oxidoreductase 1 Gene in Mice Leads to Radiation-Induced Myeloproliferative Disease Cancer Res., October 1, 2008; 68(19): 7915 - 7922. [Abstract] [Full Text] [PDF] J. A. Ross Environmental and Genetic Susceptibility to MLL-Defined Infant Leukemia J Natl Cancer Inst Monographs, July 1, 2008; 2008(39): 83 - 86. [Abstract] [Full Text] [PDF] G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso Therapy-related leukemia and myelodysplasia: susceptibility and incidence Haematologica, October 1, 2007; 92(10): 1389 - 1398. [Abstract] [Full Text] [PDF] C. Infante-Rivard, J. K. Vermunt, and C. R. Weinberg Excess Transmission of the NAD(P)H:Quinone Oxidoreductase 1 (NQO1) C609T Polymorphism in Families of Children with Acute Lymphoblastic Leukemia Am. J. Epidemiol., June 1, 2007; 165(11): 1248 - 1254. [Abstract] [Full Text] [PDF] P. Bolufer, M. Collado, E. Barragan, J. Cervera, M.-J. Calasanz, D. Colomer, J. Roman-Gomez, and M. A. Sanz The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia Haematologica, March 1, 2007; 92(3): 308 - 314. [Abstract] [Full Text] [PDF] J. Healy, H. Belanger, P. Beaulieu, M. Lariviere, D. Labuda, and D. Sinnett Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia Blood, January 15, 2007; 109(2): 683 - 692. [Abstract] [Full Text] [PDF] L. G. Spector, S. M. Davies, L. L. Robison, J. M. Hilden, M. Roesler, and J. A. Ross Birth Characteristics, Maternal Reproductive History, and the Risk of Infant Leukemia: A Report from the Children's Oncology Group Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 128 - 134. [Abstract] [Full Text] [PDF] L. G. Spector, Y. Xie, L. L. Robison, N. A. Heerema, J. M. Hilden, B. Lange, C. A. Felix, S. M. Davies, J. Slavin, J. D. Potter, et al. Maternal Diet and Infant Leukemia: The DNA Topoisomerase II Inhibitor Hypothesis: A Report from the Children's Oncology Group Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 651 - 655. [Abstract] [Full Text] [PDF] S. H. Wilson and K. Olden The Environmental Genome Project: Phase I and Beyond Mol. Interv., June 1, 2004; 4(3): 147 - 156. [Abstract] [Full Text] [PDF] C.-H. Pui, M. V. Relling, and J. R. Downing Acute Lymphoblastic Leukemia N. Engl. J. Med., April 8, 2004; 350(15): 1535 - 1548. [Full Text] [PDF] N. Wakabayashi, A. T. Dinkova-Kostova, W. D. Holtzclaw, M.-I. Kang, A. Kobayashi, M. Yamamoto, T. W. Kensler, and P. Talalay Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers PNAS, February 17, 2004; 101(7): 2040 - 2045. [Abstract] [Full Text] [PDF] D. G. Gilliland, C. T. Jordan, and C. A. Felix The Molecular Basis of Leukemia Hematology, January 1, 2004; 2004(1): 80 - 97. [Abstract] [Full Text] [PDF] M. F. Greaves, A. T. Maia, J. L. Wiemels, and A. M. Ford Leukemia in twins: lessons in natural history Blood, October 1, 2003; 102(7): 2321 - 2333. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020